Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
About $50,000 worth of trading in the last month. Active trading in March and April when the ownership info for the website changed. Not a coincidence, imo. Very little of it short volume according to otcshortreport.com. Still expecting very good results here over time. AGGX
New to the board, say hello to everyone. Hope to see great things for this stock.
Thanks. Have a good weekend and glty
beautiful.. don't see enough of these big movers anymore
nice job!
Make it 8, hit .85
aggx
.80 now. 7th new 52 week high since 6/20
aggx
Mini volume but another 52 week high. .75 now AGGX
Thanks. Glty
nice job on this one e-ore!
10,000 more shares today, now .50
5000 shares today so far. Another 52 week high. AGGX now .40 x .60
Only 100 shares but the 4th new 52 week high in the last 3 weeks. AGGX .35 x .40
AGGX filed annual list at Nevada 7/08, was in default since 3/31/16. Website still under construction. Website ownership, which used to show management as owners still hiding ownership info via "Contact Privacy Inc."
https://who.is/whois/angiogenex.com
Patented novel cancer diagnosis/cure applicable to other conditions, notably macular degeneration and rheumatoid arthritis.
Re-upping with Nevada leads me to be a little more confident that the changes here are positive.
Mini volume but another 52 week high fwiw. .35 x .45 now
Another new 52 week high .31 fwiw
AGGX deregistered via a 15-12 in 2010, going "dark," as they say. An interesting one, with Memorial Sloan Kettering a shareholder and their lead researcher is also a director and shareholder.
https://www.mskcc.org/research-areas/labs/robert-benezra
Now they're really dark. Website "under construction" since January. However it was renewed in April as a "google site" and the ownership info, which used to show management is now hidden by a privacy company (Contact Privacy, Inc.). Maybe someone out here with website ownership info skills can help me here with some info. Trading volume picked up right around when the website ownership was last updated (April 6).
https://who.is/whois/angiogenex.com
The old website had July 2016 as the start of trials, assuming funding.
They had an agreement with The Trout Group for awareness/funding but are no longer listed as a client.
http://www.troutgroup.com/clients/overview
Imo they either got funded, bought, or died :)
This article has no direct connection to AGGX but is interesting in that AGGX efforts are in the field of detection and curing of cancer.
John Battelle
Founder, EIC, CEO, NewCo
This Man's Company Is On A Mission To Cure Cancer - Why Bezos, Gates, and Google Are Backing It
June 1, 2016 • 1390 Likes • 94 Comments
Jeff Huber lost his wife Laura to cancer last fall, a loss made even more devastating by the knowledge he had gained through a mid-career shift into life sciences at Google, and board work with the gene sequencing pioneer Illumina. Just as his wife’s cancer was metastasizing beyond the reach of science, Huber was working with the Illumina board to spin out a company that promised to detect and ultimately provide the tools to beat cancer before it could spread throughout a person’s body.
After his wife’s death, Huber became CEO of the newly spun-out company. Dubbed Grail, it is backed by more than $100 million from Bill Gates, Jeff Bezos, Google, and others. Grail’s unofficial debut came via a moving commencement speech, “Find A Better Way,” that Huber gave at his alma mater in May.
Huber is best-known in the technology world as the senior engineering leader behind a 12-year hit parade of massive data businesses at Google, including Google Ads, Apps, and Maps. At Grail, he’s moved from mapping the world to mapping genomes, using Illumina’s cutting edge HiSeq sequencers?—?which, working in a pod of ten, can sequence 18,000 genomes in a year, a throughput of roughly one every few hours. Huber’s plan is to spin up scores and possibly hundreds of sequencing machines, each of which spit out a gigabit of data per second during operation. His long-term goal is nothing short of breathtaking?—?the creation of a living map of human biology, a platform spanning data and biology capable of delivering personalized cures not only for cancer, but quite possibly many other seemingly insoluble diseases.
I spoke to Huber at Grail’s San Francisco headquarters last week.
Also, this story is sent first to readers of NewCo’s just-debuted weekly newsletter. Want to get it first? Subscribe free here.
Your commencement speech at Illinois was powerful.
Thank you. The overall experience was amazing, but there were certainly parts of it that were hard to deliver. When the opportunity came up, at first I said no, since it felt too soon and too raw. But as I thought about it more, it felt like an important message to share.
I find your move to Grail interesting given your large-scale computational background. How fluent were you in science and biology?
I’m becoming fluent, but I started that direction three years ago when I moved into Google X. I ramped up the big data side of Google Life Sciences, now called Verily.
How did you move from Google X to Grail?
The decision to go focus on life sciences at Google came because I was at my 10-year anniversary. That seemed like a good opportunity to pause and reflect.
If I were contemplating another decade at Google, I didn’t want to just stumble into it. I wanted to be thoughtful. If I’m going to bite off another decade, I want to make sure I’m going into it with a lot of energy and passion.
It was really the early days of Ads, the early days of Apps, the early days of Maps that I found most exciting, and where I think I had the biggest impact for Google, from building the teams, and helping set the strategy and direction.
Also, learning new things is incredibly motivating for me. I wanted to continue challenging myself to learn, as opposed to just getting into a rut and turning the crank on the next big system, where I’d be feeling like I was doing the same thing over again.
As I thought about things I wanted to learn, it felt like the intersection of computer science and life science had the biggest potential to have an impact on the world. Biology is increasingly being digitized by technologies like genome sequencing.
If you can take things that were previously analog, incredibly complex systems like biology, and if you can digitize them and then bring the power of computation and machine learning to them, you can accelerate understanding and accelerate science dramatically.
You could have taken a different tack when you announced Grail?—?and not set the bar at curing cancer. But you chose to make the stated goal of the company a major moonshot. Are you that certain you can do it?
We certainly hope so. Timing matters, and the intersection of genome sequencing and the computation that is possible now, with new technologies like machine learning, it feels like we are at the right time to make this happen.
There’s a hell of a lot of work to be done around the fundamental understanding of the underlying biology. We’re going to have to do one of the largest scale clinical trials ever done if we are going to make the case for early detection of cancer. But it feels like now it’s finally possible. It wouldn’t have been possible five years ago.
How important is it to your investors that you follow the well-worn path of monetization that large healthcare companies take?—?create therapies and drugs, patent them, monetize them?
Grail’s purpose is to save lives. Our mission is to detect cancer early when it can be cured. We need to make the gears of capitalism work for us. We need to build an attractive business, a strong, viable business with good revenues and good margins. But it’s in service of the purpose, and in service of the mission.
The way I’ve described it to our team here, and to investors, is that Grail’s purpose is to save lives. Our mission is to detect cancer early when it can be cured. That’s the way we achieve the purpose. You could say “Oh, that’s so noble, it should be a philanthropy.” But I just haven’t seen those models work.
We need to make the gears of capitalism work for us. We need to build an attractive business, a strong, viable business with good revenues and good margins. But it’s in service of the purpose, and in service of the mission.
Do you know how you’ll make money at this? Or are you more like at the early stage of Google Maps?—?you didn’t know exactly how Maps was going to end up making money, you just knew that turning the physical world into data was going to be extremely useful and you’d figure out how to make money with it later?
The key insight in the early days of Maps was to think about it as a platform instead of a product.
That’s very NewCo. How will you be a platform? If you’re streaming a gigabit per sequencer per second, with possibly hundreds of these machines all pumping out data?—?that’s rarefied air in terms of the amount of data that you’re creating. Are you going to make that data available to authenticated platform partners?
We’re still figuring out the path, but given the underlying asset that we’re creating, this is going to be a capital-intensive business. We’re going to spend on the order of a billion dollars doing the large-scale clinical trials and building the underlying database of the genome as reflected in circulation in the blood.
The reason that the blood is interesting is it’s an integrator across many things going on in the body, and specifically what it means to have cancer, which is our focus.
Ultimately, what we want to get to is a blood test that’s integrated in the medical system. Today you go in for your annual physical exam, they already do a blood draw, and they tell you things like glucose and cholesterol levels and basic blood chemistry.
There should be one more thing you can do, which is the Grail test, which gives you the chance to detect early whether you have cancer.
I imagine this approach might identify many other kinds of diseases as well. But do people really want to know if they have them? There’s already an ethical debate about these issues …
We should give people choice to know or not. You’ll likely want to know, if there’s something you can do about it.
Historically, many of these diseases haven’t had good therapies, but increasingly they do now. Look at cancer for example. If it is detected at stage 1 or stage 2?—?with today’s treatments, it has 80 to 90 percent positive outcomes, where lives are saved.
But cancer caught later?—?at stage 3 or stage 4?—?has exactly the opposite outcomes?—?80-to-90 percent negative outcomes. So … do you want to detect cancer early?
Definitely. So will knowing the molecular makeup of a cancerous mutation?—?as you will once you sequence them?—?drive personalized new therapies?
Yes. There’s still a huge, huge way to go, but in the last five years, the new category of treatments called immunotherapies have made great strides. Contrast that with chemotherapies , the historic treatment model.
Chemo is a chemical treatment. It’s poison. The chemotherapy model is to “kill you as much as possible?—?without actually killing you.” It’s a very blunt instrument that is essentially killing fast growing cells preferentially over stable cells, which is why your hair falls out during chemo. And your stomach lining is fast growing?—?which is why patients often have terrible nausea and stomach problems during chemo.
Chemo is relatively untargeted. The new generation of immunotherapies?—?which are at a very early stage?—?basically enable your immune system to do its job. You’ve got 37 trillion cells in your body. They’re dividing all the time. You have errors all the time. Your immune system is able to detect those errors and eliminate them.
Cancer starts with literally one cell that has the right combination of mutations that let it evade the immune system?—?the immune system either can’t see it, or the cell is able to co-opt the immune system to bring it resources to grow faster. Immunotherapies help the immune system target the cancer. They will become more and more personalized over time.
So when I go to the doctor for my annual physical, I’ll find out if cancer has developed in my body that year?
In an ideal future state, you do a Grail test, and then let’s say you get the unfortunate news back that you have cancer.
The good news is that we’ve discovered it early, and we see exactly the molecular signature of what is driving your cancer. So here is a synthesized immunotherapy. It could be a shot, a vaccination. It could be a prescription. You get your synthesized immunotherapy that is targeting exactly what you have?—?it starts targeting cancer at an early stage before it’s become incredibly complex?—?when there’s a clear target to shoot at.
It isn’t chemotherapy. Your hair doesn’t fall out. You don’t puke your guts out.
You take your prescription or vaccine, and you might feel like you have a flu for a couple of weeks while your immune system wakes up and does its job. If we can, in the future, get a cancer diagnosis to being about as eventful as having the flu, that would be a good outcome.
You take your prescription or vaccine, and you might feel like you have a flu for a couple of weeks while your immune system wakes up and does its job. If we can, in the future, get a cancer diagnosis to being about as eventful as having the flu, that would be a good outcome.
Indeed it would be. Will Grail be in the business of that synthesized immunotherapy?
I don’t expect so. There’s a big industry of people working on therapeutics. And there’s a huge amount of work to do. Remember, I’m describing a future possible state we can get to a deeper understanding of cancer and next-generation treatments. This is not something that’s possible today or next year.
You could be in the business of providing the information to a platform-based ecosystem that builds those therapies.
We’re at a super early stage, but that’s the direction that makes the most sense to me right now.
Is curing cancer really an information processing problem?
That’s the biggest challenge that we’re looking at. How do you accumulate enough data, enough quality of data with the correlation to clinical records, and phenotypic information to be able to make significant correlations?
Let me get back to the question I asked earlier. You could have announced that you were doing a really important life sciences company spun out of Illumina. You didn’t have to reveal that the goal of the company was to beat cancer, and you didn’t have to name it Grail. Why did you set the true north of the company so high?
I joined the board of Illumina about two years ago. After I joined, I had a front row seat?—?I saw the technology coming along. The discussion that we had at the board level was, “The potential for impact here is huge. This is a moral and ethical imperative that it happen.”
I had seen the technology previously, and was a strong proponent of it. But at the time, my wife was going through late-stage cancer treatment. I was her primary caregiver. There’s no way I could possibly be involved. Unfortunately, Laura then passed away. But then there was an opportunity to evaluate “OK, should I approach this? Should my role be more fundamental?”
Was it called the Grail at that point?
There were a set of candidate names. When Grail came up, it instantly resonated.
I know this is sensitive, but clearly your wife’s loss must have played into your motivations to lead Grail. During the time she was in treatment, you knew of Grail’s potential?—?but that’s all it was, potential. That must have been deeply frustrating to you.
If Grail had existed five years ago, even three years ago, I am wholly, wholly confident that her journey, her outcome could have been … completely different. She would be here today. When she was diagnosed, she vowed, and I vowed along with her, that we were going to do absolutely everything possible to fight. She has probably one of the most studied cancer cases in the history of the world at this point in terms of the diagnostic testing that we did.
With all of the state-of-the-art testing available today, it yielded insights, and it affected her path of treatment, but it wasn’t enough. The reason it wasn’t enough is because it was caught so late stage. It had spread too far, and it was moving too fast.
Cancer is an evolutionary disease. It’s a disease of mutation. It starts with a single mutation, a single cell, but if you catch it after it’s gone exponential …
As an information problem, it’s way ahead of your ability to create information solutions to it.
Yeah. I felt like we were always chasing it.
Snapchat recently raised $1.3 billion. As much as I think Snapchat’s cool, they’re not exactly curing cancer. Funding a company like Grail, you need investment at a Snapchat level. Where is the next billion coming from? Do you worry about that?
I definitely worry about it. We need 10-year or 20-year investors. Back to one of your questions earlier?—?of why we declared that cancer is the thing that we’re going to tackle. It provides much stronger sense of purpose and mission. We’re not wandering the wilderness. We have a very clear, and specific focus around what we’re doing, and it’s one that is a huge importance to the world.
It must be great for attracting the right people to the business.
It attracts the right kind of team. It’s a very mission-driven organization. Everyone knows exactly what we’re doing, and the reason that people get up in the morning excited is because they see and feel the impact of it. They’ve had an experience with cancer themselves, or they’ve had a loved one who they’ve lost to cancer.
It’s incredibly motivating, and it helps us recruit the best people in the world.
Then from an investor perspective?—?people are looking for great investments, but if you can add, “Here’s the positive impact you’re having in the world while you’re making money,” that’s the next dimension.
###
If you want to share this story, please hit “Like” below. It really helps us spread the word. Thanks!
Written by
John Battelle
John Battelle
Founder, EIC, CEO, NewCo
LikeShare on LinkedInShare on FacebookShare on Twitter
1,390 likes94 comments
peter kniffin Add your comment
Birgitte Rasine Birgitte Rasine
? Storyteller and content strategist for CEOs, visionary leaders, and changemakers
John, moving piece in its own right, thanks for devoting the time to write and share it. I wonder if in your conversations and research for this piece, anyone ever mentioned the role that diet plays in preventing cancer in the first place. We always hear about technology, technology, technology, when it comes to cancer, but the problem there is that the hi-tech approach is used after the fact, after the cancer has appeared. Granted, there are plenty of people who have apparently beaten various types of cancer by changing their diet. Not to mention studies that demonstrate the power of certain natural foods, namely garlic, in fighting cancer cells. What about prevention? I understand we live in an era where cancer rates are absolutely unprecedented—as are a host of other mental and physical health issues. I do not pretend to be an expert in this area but the link between diet and health has been proven over and over again. We eat poorly, we eat processed foods, our environment is polluted, we use all kinds of products on our bodies that have all kinds of chemicals, so it seems to me we should do a lot more in the prevention area. This is one area where I would love to stop hearing about hundreds of millions of dollars invested. Because we would no longer need them.
Like(5)Reply(8)15 hours ago
LikersLori Morelli, Gina Tucker, Jeff Griffin, +2
Barry Farrell, MCE \ EVP Barry Farrell, MCE \ EVP
Producer \? Senior editor, Les Stroud Productions Survivorman Productions.
I agree with you and also with Carol.... Sometimes you need both. That Said its best to stack the odds in your favour through diet and lifestyle choices. Great article.
Like5 minutes ago
Carol Beatty Carol Beatty
Tax Manager at Carpenter Technology
People who eat only natural foods and exercise regularly also get cancer. There are long-term smokers who live very long lives and never develop cancer. Figuring out the underlying physiological why's and why not's is critical to understanding, curing and preventing cancer. Grail is an amazing undertaking and I am grateful that they are taking this monumental step.
Like(4)37 minutes ago
Likersstephen giamboi, Barry Farrell, MCE \ EVP, Jeff Huber, +1
Show More
Kevin Pezzi MD Kevin Pezzi MD
Inventor doing what Silicon Valley isn’t
Cancer is not one disease; it is MANY diseases with a variety of causes, so curing “it” will entail curing a wide spectrum of problems. If Google were committed to doing everything possible to reducing cancer (a much better interim goal than curing “it,” which President Nixon spoke of, and likely others well before him), their Google Ventures website would include contact info for innovators. I created some very practical solutions that address one of the biggest catalysts to cancer. They are easy and economical to make, and—unlike most preventive measures—are very pleasurable to use. When I told an old friend (a doctor turned venture capitalist) about some of them, he exclaimed “Holy shit!” and is eager to invest, but I’m not sure he is the best investor for this even though, as a doc, he understands cancer and sees how my breakthroughs address it in ways consumers will love.
Like(5)Reply(5)14 hours ago
LikersStephen Zielinski, Bev Farrar, Sumrina Yousuf, +2
Kevin Pezzi MD Kevin Pezzi MD
Inventor doing what Silicon Valley isn’t
@ Birgitte Rasine: Now that we're connected, I'll reply privately as soon as I can (after I take video of an unrelated prototype).
Like13 minutes ago
Birgitte Rasine Birgitte Rasine
? Storyteller and content strategist for CEOs, visionary leaders, and changemakers
Kevin Pezzi MD understood—so shall I assume it's a technology or method other than naturally existing elements?
Like(3)11 hours ago
LikersKevin Pezzi MD, Andrew Cambray, and Frankie B
Show More
Show More
.20 x .30 now
From their website which is now "under construction."
AngioGenex is a biopharmaceutical company formed to pursue the discovery and development of proprietary products for the treatment, diagnosis and prognosis of cancer. While there are numerous companies that have the same objective, none have the unique, patented technology that is being exploited by AngioGenex.
The target of the AngioGenex drug discovery effort is a previously unrecognized biological process necessary to support tumor growth that emerged from one of the most famous cancer laboratories, Memorial Sloan Kettering Cancer Center, NYC. Dr. Robert Benezra, a distinguished member of this institute, discovered that certain genes (Id genes) are actively involved in fetal growth and can be inappropriately activated in the adult to support the growth and spread of tumors. He showed that tumor growth is markedly inhibited if these genes or their proteins are even partially inactivated.
In collaboration with Dr. Benezra, AngioGenex has successfully pursued the discovery and development of molecules that inhibit the Id proteins and block tumor growth in animals. This research confirms that the Id genes are the controlling, master genes, in a unique and previously unknown process that is required for the growth and spread of tumors. A profound inhibition of tumor growth is demonstrated in animals that either have the Id genes deleted by genetic manipulation or are treated with an anti-Id drug (See Figure below).
An important finding is that the Id genes are structurally almost identical in humans as in animals suggesting that the anti-tumor effects of Id drug observed in animals will also occur in humans."
The Robert Benezra lab at Memorial Sloan Kettering
https://www.mskcc.org/research-areas/labs/robert-benezra
A/S is 150,000,000 Last known outstanding 21,302,906 as of 11/27/2009
Dr. Benezra a director, chief science officer, and shareholder of AGGX
AGGX - Major changes here over the last few months, can't confirm if they're good or bad. A strong case can be made either way. Some nice volume over the last three months, up from .10 or so to .19. I've owned some for a long time. Haven't sold any.
Website not updated yet but ownership and contact info hidden today at who.is. Hmmmm - AGGX
AGGX - .25 now with some volume in the last month :)
L2 activity has been very quiet here lately. Multiple updates today may mean we'll see the new website soon. Low ask now CSTI at .34. NITE from .10 to .90. CDEL with 71,000 shares for sale at 5.00. They can have mine at that price :) No bid support but that's normal on a thin stock like this. No reason to buy unless you're hopeful like me. But I've bought already :)
After yesterday's nibbling NITE now at .30 on the ask. Watch that change now that I've mentioned it :) If the ask goes back to .10 I may grab some more. How many dark OTC stocks have Memorial Sloan Kettering as a shareholder and are featured on the client list of The Trout Group? Not many. Only this one, imo.
http://www.troutgroup.com/clients/overview
Some nibbling today. Maybe we'll see the website update soon - AGGX
Noticed that the AGGX logo has changed in the last week. Website still being updated.
http://www.troutgroup.com/clients/overview
AGGX mentioned in this review, first time I've seen that
Age Related Macular Degeneration Pipeline Review, H2 2015 - Research and Markets
http://www.businesswire.com/news/home/20160209006111/en/Age-Related-Macular-Degeneration-Pipeline-Review-H2
Developing a novel, patented anti-cancer agent that also may be effective treating age related macular generation, rheumatoid arthritis and some symptoms of diabetes.
Their lead researcher's lab is at Memorial Sloan Kettering. Robert Benezra PhD.
MSK and Benezra are also investors/shareholders.
AGGX has patented technology here
"Uncovering new functions of a gene implicated in cancer growth opens new therapeutic possibilities
Date: April 29, 2015
Source: Weill Cornell Medical College
Summary: For the first time, researchers have shown that a gene previously implicated in blood vessel formation during embryonic development and tumor growth also induces immune suppression during tumor development. This finding opens the door for new therapeutic approaches and vaccine development in treating patients with melanoma and other advanced-staged cancers."
http://www.sciencedaily.com/releases/2015/04/150429145458.htm
AngioGenex is a biopharmaceutical company formed to pursue the discovery and development of proprietary products for the treatment, diagnosis and prognosis of cancer. While there are numerous companies that have the same objective, none have the unique, patented technology that is being exploited by AngioGenex.
The target of the AngioGenex drug discovery effort is a previously unrecognized biological process necessary to support tumor growth that emerged from one of the most famous cancer laboratories, Memorial Sloan Kettering Cancer Center, NYC. Dr. Robert Benezra, a distinguished member of this institute, discovered that certain genes (Id genes) are actively involved in fetal growth and can be inappropriately activated in the adult to support the growth and spread of tumors. He showed that tumor growth is markedly inhibited if these genes or their proteins are even partially inactivated.
In collaboration with Dr. Benezra, AngioGenex has successfully pursued the discovery and development of molecules that inhibit the Id proteins and block tumor growth in animals. This research confirms that the Id genes are the controlling, master genes, in a unique and previously unknown process that is required for the growth and spread of tumors. A profound inhibition of tumor growth is demonstrated in animals that either have the Id genes deleted by genetic manipulation or are treated with an anti-Id drug (See Figure below).
An important finding is that the Id genes are structurally almost identical in humans as in animals suggesting that the anti-tumor effects of Id drug observed in animals will also occur in humans.
http://www.angiogenex.com/technology.html
http://www.angiogenex.com/patents.html
http://www.angiogenex.com
A/S is 150,000,000 Last known outstanding 21,302,906 as of 11/27/2009 (likely more now)
The Robert Benezra lab at Memorial Sloan Kettering
https://www.mskcc.org/research-areas/labs/robert-benezra
Recent deal with The Trout Group for awareness and funding
http://www.troutgroup.com/clients/overview
AGX-51 patented by AGGX. Dr Benezra is AGGX's lead researcher, a director and a shareholder. His lab is at Memorial Sloan Kettering. MSK a shareholder too. AGGX website still under construction.
"Dr. Benezra’s team identified an agent called AGX-51 that reduces the levels of Id1 and Id3 proteins leading to a decrease in lung metastases. When combined with the commonly used chemotherapy drug Taxol, AGX-51 further reduced lung metastases in a model of aggressive breast cancer."
From here:
https://labnodes.vanderbilt.edu/member/publication/id/12249/pmid/26084673
"We then performed in vivo experiments and found that the Id1 inhibitor significantly prolonged the survival of t(8;21)(+) leukemic mice"
Been adding a little here at .09
AGGX website under construction.
"Our intention to initiate clinical trials with our lead anti-cancer drug (AGX51-E2) is now supported by a commitment from The Trout Group, a highly respected investment firm in NYC. A contractual arrangement was completed in the latter part of 2014 and efforts are currently underway to present our technology and plans to potential investors. The Trout Group is taking an active part in these efforts and we expect that we will raise sufficient funds to launch preclinical efforts to achieve FDA approval for an IND that will allow us to initiate the first clinical trial in mid-2016."
Meaningful recent developments are:
Representation by The Trout Group
http://www.troutgroup.com/clients/overview
Memorial Sloan Kettering becoming a shareholder
Robert Benezra PhD (AGGX lead researcher) becoming a board member and shareholder
AGX-51 patented by AGGX
"Breast cancer metastasis remains one of the greatest clinical challenges in breast cancer. Thus it is critical to identify new therapeutic agents that are effective in inhibiting the development of metastasis. Dr. Benezra’s laboratory is studying a class of proteins called DNA binding/differentiation (Id) proteins (Id1 and Id3) as potential therapeutic targets to prevent metastasis. Id proteins have been shown to be overexpressed in primary and metastatic breast tumors and importantly, knocking out these proteins using genetic tools leads to a near complete inhibition of metastasis in experimental models. Dr. Benezra’s team identified an agent called AGX-51 that reduces the levels of Id1 and Id3 proteins leading to a decrease in lung metastases. When combined with the commonly used chemotherapy drug Taxol, AGX-51 further reduced lung metastases in a model of aggressive breast cancer. In the coming year, they will further investigate the antitumor activity of AGX-51 to better understand how it works to regulate Id1/Id3 proteins and will identify the gene expression changes associated with this action. These experiments are key to assessing the potential for novel anti-Id therapeutics in the management of metastatic breast cancer."
http://www.bcrfcure.org/researchers/robert-benezra
Uncovering new functions of a gene implicated in cancer growth opens new therapeutic possibilities
Date:
April 29, 2015
Source:
Weill Cornell Medical College
Summary:
For the first time, researchers have shown that a gene previously implicated in blood vessel formation during embryonic development and tumor growth also induces immune suppression during tumor development. This finding opens the door for new therapeutic approaches and vaccine development in treating patients with melanoma and other advanced-staged cancers."
http://www.sciencedaily.com/releases/2015/04/150429145458.htm
AngioGenex is a biopharmaceutical company formed to pursue the discovery and development of proprietary products for the treatment, diagnosis and prognosis of cancer. While there are numerous companies that have the same objective, none have the unique, patented technology that is being exploited by AngioGenex.
The target of the AngioGenex drug discovery effort is a previously unrecognized biological process necessary to support tumor growth that emerged from one of the most famous cancer laboratories, Memorial Sloan Kettering Cancer Center, NYC. Dr. Robert Benezra, a distinguished member of this institute, discovered that certain genes (Id genes) are actively involved in fetal growth and can be inappropriately activated in the adult to support the growth and spread of tumors. He showed that tumor growth is markedly inhibited if these genes or their proteins are even partially inactivated.
In collaboration with Dr. Benezra, AngioGenex has successfully pursued the discovery and development of molecules that inhibit the Id proteins and block tumor growth in animals. This research confirms that the Id genes are the controlling, master genes, in a unique and previously unknown process that is required for the growth and spread of tumors. A profound inhibition of tumor growth is demonstrated in animals that either have the Id genes deleted by genetic manipulation or are treated with an anti-Id drug (See Figure below).
An important finding is that the Id genes are structurally almost identical in humans as in animals suggesting that the anti-tumor effects of Id drug observed in animals will also occur in humans.
"Our intention to initiate clinical trials with our lead anti-cancer drug (AGX51-E2) is now supported by a commitment from The Trout Group, a highly respected investment firm in NYC. A contractual arrangement was completed in the latter part of 2014 and efforts are currently underway to present our technology and plans to potential investors. The Trout Group is taking an active part in these efforts and we expect that we will raise sufficient funds to launch preclinical efforts to achieve FDA approval for an IND that will allow us to initiate the first clinical trial in mid-2016."
http://www.troutgroup.com/about-us/our-company
http://www.troutgroup.com/clients/overview
OS likely to be higher since they have recently let it be known (through letters to shareholders) that Memorial Sloan Kettering and their lead researcher are now shareholders. My opinion of the arrangement with The Trout Group is that it's for investor awareness to help raise funding, not funding itself. Angiogenex now showing on The Trout Group's client page. Noteworthy, imo, that AGGX is the only non-reporting tradeable stock on their client list. Why would they raise investor awareness on a stock that can't be sold by investors? :)
http://www.troutgroup.com/clients/overview
I don't know their burn rate or how much cash they have on hand. I haven't asked them because if they answered me they'd be giving me inside information. My assumption here is that they have enough friendly investor backing to keep going without having to access the capital markets for cash or they wouldn't have gone "dark."
I'll keep holding, maybe adding in the hope that the connections noted above mean that major players in the field have confidence in Angiogenex. If the science works I'm expecting a return to SEC compliant status, an eventual move to NASDAQ, and a share price in dollars, not pennies. Dream on, as my friends tell me :)
Do you think 21m OS is still valid? Do you know how much cash they have on hand (solely from Trout?) and how much they burn?
I really like improved cancer treatment
Website being updated again. Was updated about a year ago.
http://www.angiogenex.com/
In the past their timeline showed 2016 to be an important year. We'll see, and I'll keep everybody here posted
Interesting that Robert Benezra PhD is an AGGX shareholder. Memorial Sloan Kettering is as well.
http://ajp.amjpathol.org/article/S0002-9440(15)00433-2/abstract
Thought my legion of followers on this board would like to know :)
AGGX has patented technology here
"Uncovering new functions of a gene implicated in cancer growth opens new therapeutic possibilities
Date:
April 29, 2015
Source:
Weill Cornell Medical College
Summary:
For the first time, researchers have shown that a gene previously implicated in blood vessel formation during embryonic development and tumor growth also induces immune suppression during tumor development. This finding opens the door for new therapeutic approaches and vaccine development in treating patients with melanoma and other advanced-staged cancers."
http://www.sciencedaily.com/releases/2015/04/150429145458.htm
AngioGenex is a biopharmaceutical company formed to pursue the discovery and development of proprietary products for the treatment, diagnosis and prognosis of cancer. While there are numerous companies that have the same objective, none have the unique, patented technology that is being exploited by AngioGenex.
The target of the AngioGenex drug discovery effort is a previously unrecognized biological process necessary to support tumor growth that emerged from one of the most famous cancer laboratories, Memorial Sloan Kettering Cancer Center, NYC. Dr. Robert Benezra, a distinguished member of this institute, discovered that certain genes (Id genes) are actively involved in fetal growth and can be inappropriately activated in the adult to support the growth and spread of tumors. He showed that tumor growth is markedly inhibited if these genes or their proteins are even partially inactivated.
In collaboration with Dr. Benezra, AngioGenex has successfully pursued the discovery and development of molecules that inhibit the Id proteins and block tumor growth in animals. This research confirms that the Id genes are the controlling, master genes, in a unique and previously unknown process that is required for the growth and spread of tumors. A profound inhibition of tumor growth is demonstrated in animals that either have the Id genes deleted by genetic manipulation or are treated with an anti-Id drug (See Figure below).
An important finding is that the Id genes are structurally almost identical in humans as in animals suggesting that the anti-tumor effects of Id drug observed in animals will also occur in humans.
http://www.angiogenex.com/technology.html
http://www.angiogenex.com/patents.html
My personal opinion is that AGGX will resume filing with the SEC at some point soon. It is my opinion also that they went dark in their early stages because they had deep-pocket friendly investors thus there has been no need to go the toxic financing route. Their patented anti cancer treatment is novel and has been very effective in animal testing. Clinical trials possible later this year
Chief research scientist for AGGX is Robert Benezra, PhD, a noted researcher
https://www.mskcc.org/research-areas/labs/robert-benezra
http://archive.sciencewatch.com/inter/aut/2011/11-mar/11marBene/
http://www.bcrfcure.org/researchers/robert-benezra
From Bloomberg:
"Dr. Robert Benezra, Ph.D. serves as Chairman of Scientific Advisory Board and Chief Scientific Officer at AngioGenex, Inc. Dr. Benezra has been a Member of Scientific Advisory Board of Provista Diagnostics, Inc. since June 28, 2012. Dr. Benezra serves as a Member of the Cell Biology Program at Memorial Sloan-Kettering Cancer Center. Dr. Benezra is Professor of Biology at Cornell Graduate School of Medical Sciences in New York City. Before joining Sloan-Kettering, Dr. Benezra worked at Fred Hutchinson Cancer Center in Seattle where he identified the Id proteins as dominant negative regulators of the helix-loop-helix protein family and has gone on to identify these proteins as key regulators of tumor growth, angiogenesis and metastasis. Dr. Benezra has been a Director of AngioGenex, Inc. since June 18, 2014. He has received fellowships and grant awards from the National Institutes of Health, the National Science Foundation and the American Cancer Society. Dr. Benezra received his doctorate in Biological Sciences at Columbia University in 1996."
I know this company is "dark" but there's a lot going on here. Memorial Sloan Kettering now a shareholder/investor. Deal in the works with The Trout Group. Their patented anti-cancer drug (that blocks tumor-associated new blood vessel formation and prevents tumor growth) also being considered as a treatment for macular degeneration, rheumatoid arthritis and diabetes. Their latest shareholder letter:
Dear AngioGenex Shareholder:
I am pleased to report that important progress was achieved by the Company in 2014. In particular, there has been a significant expansion of our knowledge of our potent anti-cancer drug, AGX51, a molecule that has the potential to have many advantages for use as an anti-cancer therapeutic. AGX51 is a small molecule that is easily and cheaply synthesized and, based on testing in a number of animal tumors, there is evidence that it has the potential to be used orally to treat many types of cancers. The potency and safety of this molecule was markedly increased this year by separating the two mirror-like entities (enantiomers) that constitute AGX51 into a highly active part (AGX51E-2) and relatively inactive part (AGX51E-1). The Company plans to bring the pure active form, AGX51E-2, into clinical testing in combination with a standard chemotherapeutic drug such as Taxol. Adding a second drug to treat cancer is common practice and it is one of the quickest and most effective ways to assess the anti-tumor effects of our drug. If results in man are similar to those observed in animals, it is expected that there will be a significant augmentation of the anti-cancer effect and a reduction in the toxicity of the chemotherapeutic.
More recent research demonstrated that AGX51-E2 has the unusual and highly desirable property of blocking metastasis in extremely challenging animal models. Since metastasis is highly detrimental to cancer patients, it is our intention to test the ability of AGX51E-2 to block this process in man. We are greatly encouraged by the interest the clinical staff at the Memorial Sloan Kettering Cancer Center (MSKCC) has expressed in participating in these trials.
Progress was also achieved with our ocular program. Dr. Glenn Stoller, a member of our Ocular Scientific Advisory Board, reported significant advances in the Company’s ocular program with AGX51E-2 at the national Bascom-Palmer Symposium where he provided experimental results showing that AGX51E-2 is highly active in the animal model of human age related macular degeneration that predicted the clinical success of Lucentis (Genentech) and Eylea (Regeneron). AGX51-E2 was found more protective than Eylea in this model. The Company is pursuing opportunities for collaboration with an ocular company for the development of AGX51E-2 for the treatment of age related macular degeneration. Finally, we are pleased to report that in 2014 Memorial Sloan Kettering Cancer Center became an AngioGenex shareholder, and allowed our Chief Scientific Officer, Dr. Robert Benezra, to become a member of the AngioGenex Board of Directors.
Sincerely,
Richard Salvador
Chairman and President
AGGX - Biggest volume in almost a year. My chart analysis says this will follow through.
AGGX 2015 product pipeline report just released. Not paying the $750 for it; Interesting that it's available though
https://marketpublishers.com/report/life_sciences/medical_devices/angiogenex-inc-product-pipeline-analysis-2015-update.html
I still am thinking this company will re-register with the SEC and be "real" again
http://www.angiogenex.com/pipeline.html
First time I've seen diabetes and rheumatoid arthritis mentioned as possible uses for their patented product. New addition to the website:
Competitive Advantages of AngioGenex Technology
Innovation/novel application of Id technology. The Id genes are required for the growth and spread of tumors and these actions are inhibited by the anti-Id drugs such as AGX51. The anti-Id drugs have been shown to have few if any side effects since they do not interfere with normal body functions, and are unlikely to cause resistance that can occur with anti-cancer therapy.
Compelling scientific data. Tumor growth is inhibited in multiple animal models in the absence or even a partial reduction in the Id genes. These results have been duplicated with use of anti-Id drugs such as AGX51, the most potent molecule of two chemical series discovered and patented by the Company. Some of these animal models are highly representative of the initiation and course of human disease and are likely to identify useful anti-tumor drugs.
Development of a companion diagnostic. A highly sensitive diagnostic test has been developed for the detection of Id proteins in blood and tumor tissue. This diagnostic is able to detect the presence of tumor at an early stage and is expected to be used to determine the effectiveness of anti-Id therapy and recurrence of disease.
Strategies for the clinical use of anti-Id drugs. A key clinical strategy is to couple an anti-id drug with an existing treatment such as a chemotherapeutic. Based on animal studies, the combination of an anti-Id drug in combination with a widely used cytotoxic such as Taxol is expected to be additive and possibly synergistic since the mechanism of action of these agents is different.
Application of anti-Id technology to other therapeutic areas. The anti-Id technology is being applied to non-oncologic diseases in which overgrowth of blood vessels contributes to the underlying pathology. AGX51 has been used successfully to block new blood vessel formation in the eye of an animal model of acute macular degeneration. These data are sufficient to approach potential partners. This drug will be tested in other animal models such as diabetic retinopathy and rheumatoid arthritis, diseases involving the overgrowth of blood vessels.
http://www.angiogenex.com/
Website updated. Mostly the same info, different look to it. A better look, easier for prospective investors to understand :)
http://www.angiogenex.com/
Plus some recent news. Helps to be a scientist to understand this stuff :)
"1Q, 2015: Brain penetration AGX51 one hour post extravascular administration to mice found to be excellent, ie, brain concentration of AGX51 (micrograms/gram) approximately 30% of plasma concentration (micrograms/milliliter)."
I still believe this company will resume filing with the SEC and enter the real stock world. If so, will be a nice hold.
Commitment from the Trout Group a major development here
AngioGenex, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States
"Our intention to initiate clinical trials with our lead anti-cancer drug (AGX51-E2) is now supported by a commitment from The Trout Group, a highly respected investment firm in NYC. A contractual arrangement was completed in the latter part of 2014 and efforts are currently underway to present our technology and plans to potential investors. The Trout Group is taking an active part in these efforts and we expect that we will raise sufficient funds to launch preclinical efforts to achieve FDA approval for an IND that will allow us to initiate the first clinical trial in mid-2016."
http://www.troutgroup.com/about-us/our-company
http://www.troutgroup.com/clients/overview
http://www.wallstreet-unplugged.com/agenda.pdf
Commitment from the Trout Group a major development here
"Our intention to initiate clinical trials with our lead anti-cancer drug (AGX51-E2) is now supported by a commitment from The Trout Group, a highly respected investment firm in NYC. A contractual arrangement was completed in the latter part of 2014 and efforts are currently underway to present our technology and plans to potential investors. The Trout Group is taking an active part in these efforts and we expect that we will raise sufficient funds to launch preclinical efforts to achieve FDA approval for an IND that will allow us to initiate the first clinical trial in mid-2016."
http://www.troutgroup.com/about-us/our-company
http://www.troutgroup.com/clients/overview
2015 Shareholder letter released today
Memorial Sloan Kettering now an AGGX shareholder.
Commitment from the Trout Group for support/funding
http://www.troutgroup.com/
Nice! :)
http://www.angiogenex.com/shareholder-letters.html
From the website
"4Q, 2014: Various provisional patents related to use of AGX51, eg, in ocular indications, with Taxol and related cytotoxics, with vascular disrupters, as well as activity of specific AGX enantiomers and description of an ELISA-like method to measure Ids in blood were all collected and filed in a world-wide patent filing. Anti-metastatic activity of AGX51 found to reside predominately in one enanatiomer."
Not worried about them being "dark." Actually I'm pleased that they went that route to save money. What if they went "dark" because they have a wealthy inside investor who believes? In that case there's no need for them to solicit outside investors who would undoubtedly be toxic lenders. Providing "adequate current information" allows toxic lenders to convert and dilute and without it toxic lenders won't touch AGGX with a ten foot pole.
Will their patented product be proven effective? Looks promising on 2 fronts and I'm pleased they update their website.
My biggest concern here is that it becomes the subject of an outside internet promotion. If that happens with outsiders pumping out false or misleading information then it would definitely attract the wrong kind of attention from the SEC, especially if there was a huge increase in daily volume. Being "dark" insiders can not sell shares on the open market so there's no reason for the company to promote the stock via pr announcements and such so we have seen none from the company. If it does get an outside promotion I'd sell. But I don't think that will happen; it's too thin. Best wishes...
e
AGGX thanks kindly for the update on this sleeper e-ore, and congrats on the run today! My one concern would be that they are Form 15 filers and have gone dark. That means they don't have to file periodic SEC disclosures or audited financials anymore and I'm sure you're well aware of the insuperably high threshold the SEC has to let Form 15 filers back into compliance? Just wondering what your thoughts are on this.
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
111
|
Created
|
03/01/10
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |